AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06403306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (Waterlase MD, Biolase, USA)
Description: Alternative technique introduced to clinical practice in recent years to provide hemostasis in vital pulp treatment is the usage of lasers in various wavelengths. Using lasers in pulpotomy provides many advantages such as tissue vaporization and coagulation, maintenance of a blood-free working field due to its property to close small blood vessels, minimal clot formation, and sterilization of the wound surface. Furthermore, laser systems were reported to induce cellular biostimulation. Er,Cr:YSGG lasers which belong to the Erbium laser family are the laser systems with the highest absorption rate by water, having a wavelength of 2780 nm. Besides, Erbium lasers manifest bactericidal effects.
Study NCT03440736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24)
Study NCT03440736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24)
Study NCT03440736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life-style intervention
Description: A structured program to guide weight loss and increased physical activity
Study NCT00230802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticipatory dose increase of levothyroxine
Description: as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
Study NCT00230802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxine
Description: patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week
Study NCT00230802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxine
Description: patients will increase levothyroxine by 3 extra tablets of their current dose per week.
Study NCT02871713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral Quadratus lumborum block with 0.5% ropivacaine
Description: Bilateral Quadratus lumborum block with 0.5% ropivacaine
Study NCT02871713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine with 100 mcg morphine
Description: Intrathecal Morphine with 100 mcg morphine
Study NCT00064844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gum
Description: Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
Study NCT00064844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum - Nicorette®
Description: Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.
Study NCT03839745 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Cigarette
Description: E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W, which is inclusive of the three power levels we intend to study.
Study NCT04229927 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BPDO-1603
Description: Arm1 : 1 tablet of the test drug, and 1 tablet of placebo reference drug~Arm2 : 1 tablet of the reference drug, and 1 tablet of placebo test drug
Study NCT01385449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interscalene catheter
Description: interscalene catheter
Study NCT01385449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interscalene block
Description: interscalene block
Study NCT03867305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOBIDERM
Description: Use of a MOBIDERM mobilizing band after total knee prosthesis
Study NCT00547092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 10 mg or 20 mg tadalafil tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
Study NCT00547092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: 25 mg, 50 mg, or 100 mg sildenafil citrate tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
Study NCT02573857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265
Description: Oral suspension from bulk powder
Study NCT02573857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: Oral suspension from powder in a bottle
Study NCT01489592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcuma longa
Description: oral administration of 6 grams of curcumin
Study NCT01489592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: curcuma longa
Description: oral administration of 6 grams of curcumin
Study NCT04480437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mp-BUS data collection
Description: Collect ultrasound raw data and B-mode images of all kind of breast lesions to external storage device.
Study NCT03548337 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13vPnC
Description: 13vPnC MultiDose Vial with preservative compared to a Prefilled syringe containing 13vPnC without any preservative
Study NCT01698801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg oral lenalidomide once daily on Days 1-21 of each 28-day cycle
Study NCT02871713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrathecal Morphine with 100 mcg morphine
Description: Intrathecal Morphine with 100 mcg morphine
Study NCT03428581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALND with ARM +/- LVB
Description: Subjects will undergo removal of the lymph nodes in the underarm or axilla area. This is referred to as an axillary lymph node dissection (ALND). The procedure for identifying the drainage of the arm lymphatics during an axillary dissection has been coined axillary reverse mapping (ARM). Lympho-venous bypass (LVB) is a technique incorporated along with the ARM procedure that allows preservation of the lymphatics draining the arm while removing the standard lymph nodes and not compromising the extent of the axillary dissection.
Study NCT03428581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ALND
Description: Prospective and retrospective subjects undergoing an ALND.
Study NCT01698801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg oral dexamethasone once daily on Days 1, 8, 15 and 22 of each 28-day cycle
Study NCT01183897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic
Description: This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles.Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles The patients have primary refractory BM disease. Protocol treatment is through 24 months.~Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started no later than after cycle 4 (i.e., after response is scored), but sooner if CR is achieved after cycles 1, 2, or 3, or if early HAMA develops.
Study NCT01777256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586184 50 mg
Description: GSK2586184 tablet will be administered orally as twice daily dose of 50 mg (1 x 50 mg tablet) up to 12 weeks.
Study NCT01775189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALO-02 weight-matched placebo
Description: crushed sugar spheres (powder) x 1 dose
Study NCT01775189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crushed ALO-02 30 mg/3.6 mg
Description: crushed ALO-02 30 mg/3.6 mg capsule x 1 dose
Study NCT01775189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxycodone weight-matched placebo
Description: crushed lactose tablets (powder) x 1 dose
Study NCT01775189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: crushed oxycodone IR 30 mg
Description: Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose
Study NCT03638414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePainQ questionnaire
Description: This is a questionnaire which will be given to the intervention group about their perceptions of treatment. It will be online.
Study NCT04005014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myopia prediction algorithm
Description: Candidate predictors included age at examination, SE, and annual progression rate. Using these predictors, the algorithm will be used to predict SE and whether patients will progress to high myopia in the subsequent 10 years.
Study NCT01028924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teduglutide
Description: subcutaneous (SC), single dose
Study NCT01028924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teduglutide
Description: subcutaneous (SC), single dose
Study NCT01028924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: subcutaneous (SC), single dose
Study NCT04131738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib may be taken without regard to food. It should be taken at the same time every day.
Study NCT02329535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Description: vaginal caps 400 mg daily up to 36 weeks of gestation
Study NCT00637767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan
Study NCT00637767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT00637767 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous hematopoietic stem cell transplantation
Study NCT00637767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Study NCT00637767 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183
Study NCT03218124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remifentanil Effect site concentration
Description: After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method).
Study NCT03482258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This equates to 10g GOS (VGOS is primarily 69% GOS, 23% Lactose).
Study NCT03482258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This will be matched to VGOS for lactose (3.3g per dose of maltodextrin will be lactose).
Study NCT03242200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mobile Health App
Description: Mobile Health is a multi-featured app designed to enable participants to self-record and track their health and wellness. Participations will set up a profile and complete questionnaires. The app also records the amount of time and features of programs accessed.
Study NCT01613313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.
Study NCT03301571 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Change in preload and afterload
Description: Afterload: Three levels of positive end-expiratory pressure (PEEP) will be examined post-operatively: 0 cm H20, 5 cm H2O, 10 cm H2O Preload: Trendelenburg position for 5 minutes will be investigated
Study NCT03301571 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inspired oxygen
Description: Following fractions of inspired O2 will be investigated: 0.5 and 1.0 for 10 minutes respectively
Study NCT03301571 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pacemaker mode
Description: Following pacemaker settings will be investigated: Atrioventricular pacing 10 bpm over the patients' intrinsic rhythm, atrial pacing 10 bpm over the patients' intrinsic rhythm, ventricular pacing 10 bpm over the patients' intrinsic rhythm
Study NCT06290908 — intervention group
Intervention type: PROCEDURE
Intervention: RPE-P/TLIF
Description: patients with lumbar spinal stenosis and instability who met the inclusion and exclusion criteria were treated with RPE-P/TLIF
Study NCT04207489 — intervention group
Intervention type: PROCEDURE
Intervention: endoscopic submucosal injection of indocyanine green before laparoscopic radical operation of colorectal cancer
Description: Indocyanine green was injected under endoscope within 24 hours before operation. Four points were evenlyinjected in four quadrants at the edge of the tumor. The patients with obstruction were injected at two points on the anal side of the tumor. The diluted concentration of indocyanine green was 0.625mg/ml or 1.25mg/ml. The injection method was direct submucosal injection and sandwich method. According to the imaging effect, it can be divided into local imaging and lymphatic drainage imaging. Tumor body: 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation. Lymph drainage area imaging 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation.
Study NCT01484327 — intervention group
Intervention type: DRUG
Intervention: Carvedilol
Description: Minimum dosage 3.125 mg Χ 2, Maximum dosage 50 mg
Study NCT00843635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Given orally
Study NCT03398642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: French Lifestyle Redesign
Description: Lifestyle Redesign® is a preventive occupational therapy intervention designed to promote meaningful and healthy activities. The French-Canadian Lifestyle Redesign® intervention was led by an occupational therapist (OT) who took the University of Southern California 6-hour online introductory training course and was supervised on a weekly basis. Weekly 2-hour group sessions were held over a six-month period.These sessions were based on 12 modules (e.g. occupation, health and aging; transportation and occupation) from the 2nd edition of the Lifestyle Redesign® Manual and involved didactic presentations, peer exchanges, reflective exercises, direct experience and personal exploration. Every month, one group outing was targeted and individual meetings with the OT were planned.
Study NCT03341364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-based group therapy
Description: 6 group therapy sessions over 6 weeks (one session à 2 hours weekly), plus one follow-up session 6 weeks after last session. The sessions are lead by a psychologist and a social worker. Each session containing discussions, experimental exercises and home-work assignment.
Study NCT03341364 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT individual treatment
Description: 3-12 individual therapy sessions over 3-16 weeks, plus one follow-up session 6 weeks after last session, lead by a clinical psychologist. Each session containing discussion, experimental exercises and home-work assignment.
Study NCT01368172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Guidelines
Description: Participants in the Physical Activity Guidelines Arm will be asked to participate in at least 20 minutes of moderate to heavy intensity aerobic activity 2 times per week as well as strength training exercises (moderate intensity) 2 times per week. The Control Arm will not be supervised to follow the physical activity guidelines
Study NCT05927675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The exercise intervention program consisted of two distinct periods. During period 1, subjects participated in a moderate to vigorous intensity exercise program for 40 minutes a day, 4 days a week. The exercise program was conducted in Tabata format targeting 70% of the maximum heart rate. Recovery was then induced for 1 minute and 30 seconds, allowing the heart rate to return to resting levels. The exercise routine primarily consisted of full-body exercises, functional training, and power exercises.~During period 2, a low-intensity static exercise program was implemented. Similar to period 1, the subjects exercised for 40 minutes a day, 4 days a week. The exercise program included static exercises. The maximum heart rate was maintained below 50%. The detailed exercise program consisted of stretching movements and balance movements.
Study NCT02797665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: prednisone 0.6mg/kg/d
Study NCT03225625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paraspinal
Description: BMSC provided by paraspinal injection, intravenous and intranasal
Study NCT01777256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586184 100 mg
Description: GSK2586184 tablet will be administered orally as twice daily dose of (2 X 50 mg tablet) up to 12 weeks.
Study NCT01777256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586184 200 mg
Description: GSK2586184 tablet will be administered orally as twice daily dose of 200 mg (1 x 200 mg) up to 12 weeks.
Study NCT00843635 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study NCT02506283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zamar Therapy CT clinic
Description: Zamar Therapy is a certified medical product (directive 93/42/EEC and ISO 134 85:2012) (www.zamarmedical.com)
Study NCT02506283 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Zamar Therapy CT clinic
Description: Zamar Therapy is a certified medical product (directive 93/42/EEC and ISO 134 85:2012) (www.zamarmedical.com)
Study NCT00476775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: after school ethnic dance program - ballet folklorica
Study NCT00476775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: culturally-tailored, home-based screen time reduction
Study NCT00476775 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: culturally-tailored health and nutrition education
Study NCT03244644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBX2660
Description: RBX2660 is a rectally administered microbiota suspension
Study NCT03244644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is normal saline solution administered rectally
Study NCT03244644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Open label RBX2660 (only for confirmed CDI recurrence)
Description: RBX2660 administered as a second treatment after confirmed CDI recurrence following the initial dose of placebo or RBX2660
Study NCT03244644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open label RBX2660 (only for confirmed CDI recurrence)
Description: RBX2660 administered as a second treatment after confirmed CDI recurrence following the initial dose of placebo or RBX2660
Study NCT01777256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586184 400 mg
Description: GSK2586184 tablet will be administered orally as twice daily dose of (2 X 200 mg) up to 12 weeks.
Study NCT04414345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNM-Au8
Description: Drug: CNM-Au8~Administration: Oral~Dosage: 30 mg or 60 mg daily
Study NCT04414345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Drug: Matching Placebo~Administration: Oral~Dosage: 2 bottles daily
Study NCT03390426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: An ultrasound guided injection of mepivacaine superomedially to the femoral artery.
Study NCT03390426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perifemoral Injection of Local Anesthetic
Description: An ultrasound guided injection of mepivacaine superomedially to the formal artery in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.
Study NCT03390426 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Perifemoral Injection of Local Anesthetic
Description: An ultrasound guided injection of mepivacaine superomedially to the formal artery in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.
Study NCT03390426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: An ultrasound guided injection using a medication that does NOT numb any nerves called saline, or salt water.